GSK-Galapagos' autoimmune disease drug enters midstage trials

02/6/2013 | Pharmaceutical Business Review Online · Reuters

GlaxoSmithKline is preparing midstage trials to assess the experimental drug GSK2586184 in patients with systemic lupus erythematosus and chronic plaque psoriasis. GSK2586184, a selective JAK1 molecule, was identified under Galapagos and GSK's osteoarthritis collaboration.

View Full Article in:

Pharmaceutical Business Review Online · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ